HYTERA
9.6.2020 03:02:05 CEST | Business Wire | Press release
Imagine one day you get a traffic ticket from the police officers with the penalty amount stating: "Stay Home". Recently, movement restriction rules are being enforced in every Emirate in the UAE. In Abu Dhabi, the police officers patrol the streets round the clock and stress the need for people to stay home. They also urge the community to practice social distancing measures and to wear masks and gloves, when stepping out. The effect and efficiency of their work is being guaranteed by Hytera’s Narrowband & Broadband Convergent Communication Solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005013/en/
“During the day, we spread awareness that people should not step out during Sanitization Program and if we spot anyone not wearing a mask, we tell them to put it on. We would give a warning to first-time offenders and impose a Dh 1,000 fine if they're found outside again,” said one of the police officers from the patrols unit. Abu Dhabi Police is responsible for enforcing the compliance with the UAE federal law.
To prevent the spread of Coronavirus, police officers bear an important responsibility for ensuring the public's commitment to the national movement restrictions. The availability of reliable communication services has become an indispensable part to better safeguard citizens both in times of crisis and in normal day-to-day operations.
Abu Dhabi Police have adopted Hytera Narrowband & Broadband Convergent Communication Solution in 2019. Patrol vehicles were equipped with the Hytera Smart devices which support 2G/3G/4G and LTE. This provided the police officers with a converged radio and a smartphone supporting both narrowband and broadband technologies. Smart devices deliver key voice services through the built-in TETRA module, thereby guaranteeing the reliability and security of the Abu Dhabi Police’s daily voice communications. The LTE and Wi-Fi part of the radio provide the broadband data services and application software to support multimedia services, and smart applications used by the Police Enforcement to execute different tasks online, transmit data to the data center and send the required message or safety instructions to the public.
The built-in GPS location functionality of Hytera Smart Devices combined with integrated mapping systems and compasses can upload GPS locations to the Command and Control Center which makes the dispatch task more efficient.
“It is certainly a challenging time for everyone as the pandemic brings significant impact on our life. Many of our users like police and healthcare providers are in the front line of fighting against the virus. As a manufacturer, we believe the secure and reliable communications can make their work more efficient and effective. And as citizens, we all need to practice social distancing to minimize the risk of COVID-19 spreading in the community,” said Stanley Song, Director of the Middle East and North Africa region for Hytera.
For more information, please visit: https://bit.ly/36XU5Dz
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
